NewTimeSpace News: Shanghai Henlius Biotech, Ltd. (02696.HK) announced on 17 June that Hanbeiyou (pertuzumab injection) has passed GMP compliance inspection issued by Shanghai Municipal Drug Administration. The Songjiang manufacturing base is now qualified for domestic commercial production of the product. Independently developed pertuzumab biosimilar for HER2-positive breast cancer, Hanbeiyou has obtained marketing approvals in China, the US and EU. Domestic sales of pertuzumab products reached approximately RMB2.728 billion in 2025 per IQVIA CHPA data.
NewTimeSpace News: Giant Biogene Holding Co., Ltd. (02367.HK) announced that its wholly-owned subsidiary Shaanxi Giant Biotech Co., Ltd. has received the Medical Device Registration Certificate issued by the National Medical Products Administration (NMPA) for its Cross-linked Recombinant Collagen Implant. The product is designed for intradermal dermal injection and filling of the neck to correct moderate-to-severe horizontal neck lines, making it the world’s first cross-linked recombinant Type III collagen filler dedicated to neck wrinkle treatment.
NewTimeSpace News: As of 15:33 on June 17, 2026, BIDU-SW(09888.HK) trended stronger, quoting HK$111.8 intra-day, representing a 0.99% gain. Apollo Go, Baidu’s autonomous driving arm, has officially entered Switzerland. Its self-driving service AmiGo, developed jointly with local public transport operator PostBus, has started public road testing.
NewTimeSpace (newtimespace.com) News: On June 17, 2026, the chip sector fluctuated and strengthened. The share price of Hua Hong Semiconductor Limited (01347.HK) rose substantially. As of 13:44 PM, the company's share price was quoted at HK$156.200, up 6.48%.
Mininglamp Technology (2718.HK) Under the trend where Edge AI transitions from a "concept" to a "trillion-dollar industrial blueprint" and AI Agents race from a "tens-of-billions track" toward a "three-hundred-billion market," the company is validating a core proposition through its differentiated path of "Scaling Out."
NewTimeSpace (newtimespace.com) News: On June 17, 2026, the humanoid robot sector fluctuated and weakened. Midea Group (00300.HK) fluctuated downward, with the company's share price quoted at HK$89.250, down 1.00% as of 13:17 PM.
Choice data shows that on June 16, 2026,First Seafront Artificial Intelligence Dynamic Allocation Hybrid Fund-A (001986) and First Seafront Artificial Intelligence Dynamic Allocation Hybrid Fund-C (023286) recorded gains of 5.35% respectively. Over the past three months,First Seafront Artificial Intelligence Dynamic Allocation Hybrid Fund-A (001986) and Mixed C (023286) have jumped by 78.10% and 77.92% respectively.
Newtimespace.com reports: MicroPort MedBot (2252.HK) announced that Toumo endoscopic surgical robot global commercial orders have exceeded 300 units, with H1 new orders surpassing full-year 2024 total and comprehensive orders nearing 400 units. Toumo has achieved commercial installation in over 60 countries and recently completed the world's first Starlink satellite-enabled robotic remote surgery, with annual production capacity exceeding 500 units.
NewTimesSpace (newtimespace.com) reports: Keytop Parking (2272.HK) launched its subscription on June 17, offering approximately 10.11 million H shares globally at HK$39.55 per share. The entry fee for one board lot of 60 shares is approximately HK$2,397. The listing is expected on June 26, with CICC and CMBC Capital serving as joint sponsors.
New Times Space (newtimespace.com) reports: Lingyi iTech (1688.HK) launched its subscription on June 17, offering approximately 811.81 million H shares globally at a maximum price of HK$10.18 per share. The entry fee for one board lot of 660 shares is approximately HK$6,787. The listing is expected on June 26, with Guotai Haitong and Guotai Junan International serving as exclusive sponsors.
NewTimesSpace (newtimespace.com) reports: CFMEE (9630.HK) launched its subscription on June 17, offering approximately 12.84 million H shares globally at a maximum price of HK$252.73 per share. The entry fee for one board lot of 50 shares is approximately HK$12,764. The listing is expected on June 26, with CICC serving as the exclusive sponsor.
NewTimeSpace News: Hengrui Medicine announced on June 16 that SHR-6914 Injection developed by its subsidiary Suzhou Shengdiya Biomedicine Co., Ltd. has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving clinical trials for its monotherapy in the treatment of prostate cancer.
NewTimeSpace News: Regent Pacific Group announced in an announcement dated June 16 that the New Drug Application for its proprietary Senstend™ has been approved by the National Medical Products Administration, with a four-year data protection period attached.
NewTimeSpace News: CSPC Pharmaceutical Group announced on June 16 that the New Drug Application (NDA) for its self-developed Valsartan Levoamlodipine Maleate Tablets (Tablet SYH9056) has been accepted by the National Medical Products Administration.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the Phase 2 clinical trial of HLX43 for Injection, a PD-L1-targeted antibody-drug conjugate (ADC), in combination with Hansizhu® (serplulimab injection) for neoadjuvant therapy of non-small cell lung cancer (NSCLC), has obtained approval from the relevant Human Research Ethics Committee (HREC) of Australia and completed Clinical Trial Notification (CTN) filing with the Therapeutic Goods Administration (TGA). Previously, key subgroup data of HLX43 in NSCLC were presented as a rapid oral abstract at the 2026 ASCO Annual Meeting.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the global multicenter Phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for the treatment of wet age-related macular degeneration (wAMD), has reached its primary endpoint. The trial results demonstrated that the mean change in best corrected visual acuity (BCVA) from baseline at Week 36 and Week 48 in the HLX04-O group was non-inferior to that of the ranibizumab group, with a favorable safety profile.
